RICHMOND, British Columbia, Feb. 19, 2009 (GLOBE NEWSWIRE) --
BioCurex Inc. (OTCBB:BOCX) today reported on its RECAF presentation
at this international cancer congress held in Barcelona, Spain.
Four months ago, BioCurex, represented by Dr. Ricardo Moro, was
invited to present results on its cancer marker RECAF at this
prestigious meeting. The congress gathered close to 400 specialists
in cancer markers worldwide, with the majority being from Europe,
where cancer markers are extensively used and BioCurex holds issued
patents.
This meeting is very focused on the clinical uses of tumor
markers and it brings together physicians who use cancer markers,
clinical chemists who carry out the tests and companies that develop
or produce tests for cancer diagnosis. It is an ideal forum to
present results on a novel cancer marker and as such, BioCurex's
RECAF draw a great deal of attention.
Dr. Moro's presentation - in a plenary session - was very well
received and as a result, two top clinical chemistry groups
expressed an interest in developing collaborations with BioCurex to
independently validate the usefulness of RECAF in the clinical
environment as well as to further advance the research on this
marker. The directors of these teams are members of the European
Group on Tumor Markers, an institution heavily involved in creating
the recommendations for the use of cancer markers in the European
Union, which are also followed by other countries. These two
scientists have published over 250 scientific papers on the use of
cancer markers.
Dr. Moro stated: "We are very pleased with the interest elicited
by our results. These collaborations translate into several
important elements for BioCurex:
* They will work completely independently from BioCurex and therefore
the data thus produced can be used for regulatory purposes not only
in Europe, but also in America.
* They will perform all the work at their expense with the exception
of the cost of the tests, which BioCurex will initially provide
free of cost.
* The two groups evaluate and publish results for diagnostic products
marketed by large diagnostic companies, including Abbott and Roche,
and therefore their opinions and recommendations are important for
companies working in the field.
* Finally, since these scientists are leaders in the field; their
independent validation of our results may prompt of other
scientists to work with RECAF, which besides the obvious scientific
impact could also become a source of revenue.
We are honored by their interest to work with us and we are
looking forward to developing these collaborations in the near
future, as well as continuing the ones that we have already
established."
For more information on the XII International Symposium on
Biology and Clinical Usefulness of Tumor Markers visit http://www.oncolab.net/informationingle09.html
For information on the European Group on Tumor Markers, visit
http://egtm.eu/
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing
products based on patented/proprietary technology in the areas of
cancer diagnosis, imaging and therapy. The technology identifies a
cancer marker known as RECAF(tm), which is found on malignant cells
from a variety of cancer types but is absent in most normal or
benign cells.
BioCurex has signed licensing agreements for its cancer detection
blood tests with Abbott Laboratories and with Inverness Medical
Innovations (for further information on these agreements see:
http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt).
The cancer marker RECAF(tm) has emerged as a potential biomarker
that may be useful in the development of new cancer diagnostics
tests. Preliminary studies from the investigators at BioCurex have
reported a high level of clinical sensitivity and specificity for
RECAF in many of the most common cancers, including prostate,
breast, colorectal, lung and others.
To read more about the Company, please visit the News section in
our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in
any form that contravenes the Communication Act and will not be
responsible for unsolicited massive distribution of this material by
e-mail or facsimile by unauthorized parties. Statements in this
press release, which are not historical facts, are "forward-looking
statements" within the meaning given to that term in the Private
Securities Litigation Reform Act of 1995. The Company intends that
such forward-looking statements be subject to the safe harbors
created thereby. Since these statements involve risks and
uncertainties and are subject to change at any time, the Company's
actual results could differ materially from expected results.
Contacts:
BioCurex, Inc.
Ricardo Moro
(604) 207-9150
Website: www.biocurex.com
AGORACOM
Investor Relations
Website:
www.agoracom.com/IR/Biocurex
